A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder

Psychoneuroendocrinology. 2006 May;31(4):543-7. doi: 10.1016/j.psyneuen.2005.11.001. Epub 2005 Dec 13.


We tested and compared the use of two adjunctive hormonal agents, tamoxifen and medroxyprogesterone acetate (MPA), for the treatment of acute mania or hypomania. A total of 13 women with acute Bipolar Affective Disorder in the manic or hypomanic phase were recruited from a clinical population to participate in this 28-day, three-arm, double blind, placebo-controlled study. The women who received tamoxifen exhibited significant improvement in symptoms of mania from baseline to final assessment compared with the placebo group. The MPA group improved more than the placebo group. Further exploration of tamoxifen as a useful adjunct in the treatment of acute manic symptoms in women with Bipolar Affective Disorder is warranted.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Analysis of Variance
  • Antimanic Agents / therapeutic use*
  • Bipolar Disorder / blood
  • Bipolar Disorder / drug therapy*
  • Double-Blind Method
  • Estradiol / blood
  • Estrogen Antagonists / therapeutic use
  • Female
  • Humans
  • Medroxyprogesterone / therapeutic use*
  • Middle Aged
  • Pilot Projects
  • Progesterone Congeners / therapeutic use
  • Psychiatric Status Rating Scales
  • Statistics, Nonparametric
  • Tamoxifen / therapeutic use*
  • Treatment Outcome


  • Antimanic Agents
  • Estrogen Antagonists
  • Progesterone Congeners
  • Tamoxifen
  • Estradiol
  • Medroxyprogesterone